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In tro duc ti on
Absence of adequate retrospective data and lack of 
record keeping in health care systems have been identified 
as important problems. Registry systems for follow-up of 
patients with type 1 diabetes mellitus (T1DM) have been in 
practice in many countries for years. With these systems, it 
has been possible to monitor quality of life in diabetic patients 
nationally, to obtain data about metabolic control and clinical 
ABS TRACT
Ob jec ti ve: Epidemiologic and clinical features of type 1 diabetes mellitus 
(T1DM) may show substantial differences among countries. The primary 
goal in the management of T1DM is to prevent micro- and macrovascular 
complications by achieving good glycemic control. The present study aimed 
to assess metabolic control, presence of concomitant autoimmune diseases, 
and of acute and long-term complications in patients diagnosed with T1DM 
during childhood and adolescence. The study also aimed to be a first step in the 
development of a national registry system for T1DM, in Turkey. 
Methods: Based on hospital records, this cross-sectional, multicenter study 
included 1 032 patients with T1DM from 12 different centers in Turkey, in whom 
the diagnosis was established during childhood. Epidemiological and clinical 
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course in these patients, and to develop standards for the 
treatment and monitoring of diabetes (1).
With this cross-sectional, multicenter study, we aimed 
to assess metabolic control, presence of concomitant 
autoimmune diseases as well as the microvascular and acute 
complications of diabetes in patients diagnosed with T1DM 
during childhood and adolescence. This assessment was 
considered to be a first step in the development of a registry 
system, as well as an investigation on the state of T1DM in 
Turkey.
Methods
The diagnosis of T1DM was based on hyperglycemia 
(>200 mg/dL) and related symptoms together with ketonuria, 
ketoacidosis, insulin autoantibody (IAA) positivity, or a low 
C-peptide level. Of children/adolescents who were under 
regular follow-up in 12 different centers in Turkey, those 
who were diagnosed with T1DM before January 1, 2007 and 
who had attended at least one follow-up visit were recruited. 
Patients with normal C-peptide levels, those who were 
considered to have maturity-onset diabetes of the young 
(MODY) based on the family history and clinical findings, 
those with T2DM, and those with a chronic disease (such 
as thalassemia, cystic fibrosis, drug-induced types) were 
excluded from the study. The data on the demographic and 
clinical characteristics of the patients, their anthropometric 
measurements, pubertal status, blood pressure values, 
insulin therapy regimens, the state of their metabolic control, 
lipid profile values, presence of concomitant autoimmune 
diseases, as well as acute and chronic complications were 
obtained from the patients’ files. The patients were grouped 
according to their hemoglobin A1c (HbA1c) levels in the past 
year. Those with good metabolic control (<7.5%) constituted 
Group 1, those with moderate metabolic control (between 
7.6% and 9.0%) Group 2, and those with poor metabolic 
control (>9.0%) formed Group 3. 
Standard deviation scores (SDS) for height, weight 
and body mass index (BMI) were assessed according to 
the Turkish population standards defined by Neyzi et al (2). 
Those with a BMI ≥95th percentile were considered obese 
(3). Pubertal status of each subject was determined using 
the Tanner criteria. Metabolic control and complications were 
defined according to the International Society for Pediatric 
and Adolescent Diabetes (ISPAD) consensus criteria (4,5).
The biochemical criteria for the diagnosis of ketoacidosis 
were defined as hyperglycemia (blood glucose >11 mmol/L 
(>200 mg/dL), venous pH <7.3 or bicarbonate <15 mmol/L, 
ketonemia, and ketonuria (6). 
Severe hypoglycemia was defined as the child having an 
altered mental status and being unable to cooperate, or his/
her being semiconscious or unconscious, or in coma with or 
without convulsions and requiring parenteral therapy with 
glucagon or i.v. glucose (7). 
The diagnosis of chronic lymphocytic thyroiditis and 
of Graves’ disease were based on physical examination, 
ultrasonography, and laboratory findings including the serum 
levels of free thyroxine (fT4), thyroid-stimulating hormone 
(TSH), anti-thyroperoxidase (anti-TPO), anti-thyroglobulin 
(anti-Tg), and TSH receptor antibodies (TRAb). The patients 
were assessed as euthyroid, or as having subclinical 
hypothyroidism, hypothyroidism, or hyperthyroidism 
according to their fT4 and TSH levels (8).
Gluten-sensitive enteropathy (GSE) was diagnosed by 
presence of IgA anti-tissue transglutaminase (IgA-tTG), anti-
endomysium antibodies, and/or by biopsy findings (9). 
Retinopathy was assessed using dilated fundoscopy, non-
dilated fundoscopy, and fundus photography. Microaneurysm, 
hemorrhage, hard and soft exudates, intraretinal microvascular 
abnormalities, macular edema, proliferative retinopathy, and 
preproliferative retinopathy were accepted as the types of 
retinopathy (5).
Presence of proteinuria (≥500 mg/24 h) or albuminuria 
(≥300 mg/24 h) usually with hypertension was considered 
as evidence of diabetic nephropathy. Microalbuminuria was 
defined when one of the following was present: (i) an albumin 
excretion of 20-200 μg/min or 30-300 mg/day, (ii) an albumin/
creatinine ratio of 2.5-25 mg/mmol or 30-300 mg/g in boys 
and 3.5-25 mg/mmol in girls in the morning urine sample. 
Persistent microalbuminuria was defined as albuminuria in 
at least two of three consecutive urine samples within 3-6 
months (5).
Neuropathy was assessed by clinical examination 
and/or electromyography. Focal neuropathy (such as 
mononeuropathy/carpal tunnel syndrome), sensory-motor 
polyneuropathy, and autonomic neuropathy (such as postural 
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characteristics of the patients were recorded. Metabolic control, diabetes care, 
complications, and concomitant autoimmune diseases were evaluated. 
Results: Mean age, diabetes duration, and hemoglobin A1c level 
were 12.5±4.1 years, 4.7±3.2 years, and 8.5±1.6%, respectively. Acute 
complications noted in the past year included ketoacidosis in 5.2% of the 
patients and severe hypoglycemia in 4.9%. Chronic lymphocytic thyroiditis 
was noted in 12%, Graves’ disease in 0.1%, and celiac disease in 4.3% 
of the patients.  Chronic complications including neuropathy, retinopathy, 
and persistent microalbuminuria were present in 2.6%, 1.4%, and 5.4% of 
the patients, respectively. Diabetic nephropathy was not present in any of 
the patients. Mean diabetes duration and age of patients with neuropathy, 
retinopathy and microalbuminuria were significantly different from the 
patients without these long-term complications (p<0.01). A significant 
difference was found between pubertal and prepubertal children in terms 
of persistent microalbuminuria and neuropathy (p=0.02 and p<0.001, 
respectively). Of the patients, 4.4% (n:38) were obese and 5% had 
short stature; 17.4% of the patients had dyslipidemia, and 14% of the 
dyslipidemic patients were obese.  
Conclusions: Although the majority of the patients in the present study were 
using insulin analogues, poor glycemic control was common, and chronic 
complications were encountered.  
Key words: Type 1 diabetes, children, complications, Turkey  
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hypotension, vomiting, bladder paresis, sweating) were 
accepted as the types of diabetic neuropathy (5).
Blood pressure measurements were performed after an 
adequate rest period and were repeated at least three times 
at 10-minute intervals. Subjects with age- and sex-adjusted 
systolic and/or diastolic blood pressures above the 95th 
percentile were considered hypertensive (10). 
The presence of one or more of the following serum 
lipid values was considered as indicative of dyslipidemia: i) a 
morning fasting total cholesterol level higher than 5.18 mmol/L 
(200 mg/dL), ii) a low-density lipoprotein (LDL) level higher than 
2.6 mmol/L (100 mg/dL), or iii) a high-density lipoprotein (HDL) 
level lower than 1.1 mmol/L (42 mg/dL) (5,11).
The authors confirmed in writing that they have complied 
with the World Medical Association Declaration of Helsinki 
regulations regarding ethical conduct of research involving 
human subjects and/or animals. The study was approved by 
the local ethics board and informed consent was obtained 
from the families of all patients. 
Statistical Analysis
Data analyses were performed with SPSS for Windows 
(version 15). Patient characteristics were determined using 
descriptive statistics. Independent t-test and one-way ANOVA 
test with Bonferroni’s correction for multiple comparisons 
were used to compare the means of groups when appropriate. 
A p-value of <0.05 was chosen to represent statistical 
significance, however, bivariate correlations were considered 
significant at p<0.017 (p<0.05/3=0.017). The values are 
expressed as mean±SD.
Results
The study included 1,032 patients (mean age, 12.5±4.1 
years; 50.5% females, 49.5% males; 67.9% pubertal, 32.1% 
prepubertal), who were followed with a diagnosis of T1DM for 
a mean period of 4.7±3.2 years. The majority of the patients 
(70.4%) were aged between 10 and 20 years. The distribution 
of the patients according to age groups at the time of evaluation 
and at the time of diagnosis is presented in Table 1.
Obesity was present in 4.4% (n=38) of the patients. 
No statistically significant difference was found between 
the obese and non-obese T1DM patients in terms of age, 
diabetes duration and mean HbA1c levels of the past year 
(p>0.05) (Table 2). 
Height SDS was below -2SD in 5% of the patients.
Within the past one year, measurement of HbA1c as an 
indicator of metabolic control was performed three times 
in 35.5%, four times in 35.8%, twice in 18.4%, only once 
in 5.5% and more than four times in 4.8% the patients. 
According to these measurements, 31.6% the patients had 
good metabolic control, 33.6% had moderate metabolic 
control, and 34.8% had poor metabolic control. Mean HbA1c 
level was 8.5±1.8% at the last control visit and 8.4±1.6% in 
the past year. Mean age and mean duration of diabetes were 
shorter in Group 1 than in Groups 2 and 3 (Table 3). Moreover, 
it was found that the pubertal patients had significantly higher 
mean HbA1c levels in the past year as compared to the 
prepubertal patients (8.6±1.6 vs. 8.2±1.4, p=0.001).
Of the patients, 79.5% (694/873=67%) were on flexible 
insulin therapy (3 or more very fast-acting insulin analogues 
before meals + long-acting insulin), 5.9% were on insulin 
infusion (II) pump [continuous subcutaneous II (CSII)], 
and 3.2% were receiving multiple insulin therapy (NPH+ 
regular insulin before meals 3 times a day). Thirty (58.8%) 
of 51 patients using II pump had good metabolic control, 
whereas 12 (23.5%) had moderate metabolic control. Of the 
694 patients receiving flexible insulin therapy, 206 (29.6%) 
had good metabolic control and 236 (34.0%) had moderate 
metabolic control. Insulin therapy regimens of the patients 
and their mean HbA1c levels in the past year are presented 
in Table 4.
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Tab le 1. Distribution of the patients by age groups at the time of 
evaluation and at the time of diagnosis
Age  Number of patients  Number of patients
groups (years) at the time of   at the time 
 evaluation n (%) of diagnosis n (%)
0-4.99 39 (3.8) 280 (27.1)
5-9.99 247 (23.9) 439 (42.6)
10-14.99 418 (40.5) 288 (27.9)
15-20 298 (28.9) 25 (2.4)
≥20 30 (2.9) -
Tab le 2. Age, duration of diabetes, and hemoglobin A1c (HbA1c) 
levels in obese and non-obese type 1 diabetic patients
 Obese type 1  Non-obese type 1 p
 diabetic patients diabetic patients
 (n=38) (n=841) 
Decimal age (years) 13.4±4.8 12.5±4.2 0.08
Duration of diabetes (years) 4.8±3.2 4.8±3.3 0.48
HbA1c level (%)  8.6±1.9 8.4±1.6 0.4
(mean of past year)
Data are presented as mean±standard deviation
Tab le 3. Age and diabetes duration of the patients according to their 
mean hemoglobin A1c (HbA1c) levels
 Group 1 Group 2 Group 3  p
 (HbA1c level (HbA1c level (HbA1c level
 <7.5%)  7.5%-9.1%) ≥9.0%) 
Age* (years) 11.7±4.1 13.2±4.4 12.5±3.8 <0.001
Duration of  4.0±2.9 5.6±3.9≥ 4.7±2.8 <0.001
diabetes** (years)
Data are presented as mean±standard deviation.
*p<0.001 for Group 1 vs. Group 2; p=0.04 for Group 2 vs. Group 3




Chronic lymphocytic thyroiditis was identified in 12% 
patients and Graves’ disease in 0.1%. While 954 (93.3%) of 
all patients were euthyroid, subclinical hypothyroidism was 
found in 29 (2.8%) patients, hypothyroidism in 37 (3.6%), and 
hyperthyroidism in 2 (0.2%) patients at the time of diagnosis 
or during follow-up.
Of the patients, 4.3% were under follow-up with a diagnosis 
of GSE. GSE was diagnosed by antibody positivity alone in 16.7% 
of the patients, by biopsy alone in 5.6%, and by both antibody 
positivity and biopsy in 77.8% of the patients.
Acute Complications
During the past year, severe hypoglycemia and ketoacidosis 
episodes were observed in 4.9% and 5.2% of the patients, 
respectively. No significant difference was found among the 
groups with good, moderate, and poor metabolic control in 
terms of the number of severe hypoglycemia episodes within 
the past year (p=0.58), while the number of ketoacidosis 
episodes was significantly lower in the group with good 
metabolic control as compared to groups with moderate and 
poor metabolic control (p=0.007 and p=0.008, respectively). 
There was no significant difference between the groups with 
moderate and poor metabolic control in terms of frequency of 
ketoacidosis (p=0.91; Table 5).
Long-term Complications
Mean total cholesterol, HDL- and LDL-cholesterol levels 
were 162.5±38.8 mg/dL, 57.1±14.4 mg/dL, and 88.2±28.8 
mg/dL in the total group. These values were 166.76±39.21 
mg/dL, 58.7±14.01 mg/dL, and 90.5±29.0 mg/dL in the boys; 
158.14±37.9 mg/dL, 55.5±14.7 mg/dL, and 86.0±28.4 mg/
dL in the girls. There was no significant difference between 
the genders. The rate of dyslipidemia was 17.5%, and 8.2% 
(n=14) of these patients were obese. The majority of patients 
with dyslipidemia (75.2%) were pubertal. Patients with 
dyslipidemia were found to be older compared to the cases 
without dyslipidemia (13.2±3.9 years vs. 12.4±4.1 years, 
p=0.02). No significant difference was determined between 
the patients with and without dyslipidemia in terms of diabetes 
duration (5.2±3.2 years and 4.7±3.2 years, respectively; 
p=0.91). However, there was a significant difference between 
the patients with and without dyslipidemia in terms of the 
mean HbA1c level in the past year (9.5±2.0% and 8.2±1.4%, 
respectively; p<0.001).
Focal neuropathy, sensory-motor neuropathy, and 
polyneuropathy were identified in 1.1%, 1.1%, and 0.5% of 
the patients, respectively. The patients with neuropathy were 
significantly older compared to those without (15.8±3.9 years 
and 12.4±4.1 years, respectively; p=0.001). Mean diabetes 
duration was significantly higher in patients with neuropathy 
than in those without (8.3±4.4 years and 4.6±3.1 years, 
respectively; p=0.00). There was no significant difference 
between these two groups in terms of mean HbA1c levels 
in the past year (8.5±1.4% in those with neuropathy and 
8.4±1.6% in those without neuropathy; p=0.7).
Retinopathy was identified in 1.4% of the patients. 
Among them, 64.3% had microaneurysms, 14.3% hard 
and soft exudates, and 21.4% had proliferative retinopathy. 
Cataract was observed in 9.5% of the patients. The patients 
with retinopathy were significantly older than those without 
(16.7±3.9 years and 12.5±4.1 years, respectively; p=0.001). 
Mean diabetes duration of patients with retinopathy was also 
significantly longer than that of those without retinopathy 
(9.8±5.3 years and 4.7±3.2 years, respectively; p=0.00). There 
was no significant difference between these two groups 
regarding mean HbA1c levels in the past year (8.8±1.3% 
in those with retinopathy and 8.4±1.6% in those without 
retinopathy, p=0.3).
Diabetic nephropathy was not present in any of the 
patients, whereas persistent microalbuminuria was noted in 
5.4%. The age of patients with and without microalbuminuria 
was 15.6±3.0 years and 12.4±4.1 years; the difference was 
significant (p=0.001). The duration of diabetes was significantly 
longer in patients with microalbuminuria compared to those 
without microalbuminuria (7.2±3.9 years and 4.6±3.1 years, 
respectively; p=0.001). No significant difference regarding 
glycemic control in the past year (HbA1c, 8.8±1.4% and 
8.4±1.6%, respectively; p=0.05) was noted.
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Tab le 4. Insulin therapy regimens of the patients according to their mean hemoglobin A1c (HbA1c) levels in the past year
Insulin therapy regimens Group 1  Group 2 Group 3 Total 
 n (%) n (%) n (%) n (%)
Multiple insulin therapy (NPH+ regular insulin) 12 (4.4) 8 (2.7) 8 (2.6) 28 (3.2)
Flexible insulin therapy 206 (74.7) 236 (80.6) 252 (82.9) 694 (79.5)
Mixtard (NPH+ regular ready-mix) 6 (2.1) 6 (2.0) 7 (2.3) 19 (2.1)
Very fast-acting +NPH ready-mix 3 (1.0) 2 (0.7) 3 (1.0) 8 (0.9)
Insulin infusion pump 30 (10.9) 12 (4.1) 9 (3.0) 51 (5.9)
Other 19 (6.9) 29 (9.9) 25 (8.2) 73 (8.4)
Total n (%) 276 (100) 293 (100) 304 (100) 873 (100)
Group 1: HbA1c level (<7.5%); Group 2: HbA1c level (7.5%-9.1%); Group 3: HbA1c level (≥9.0%) 
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When the complications were evaluated according to the 
pubertal stages, nephropathy was present in 7.4% of pubertal 
patients and in 0.9% of prepubertal patients (p=0.001); 
retinopathy was present in 1.9% of pubertal patients and 
in 0.3% of prepubertal patients (p=0.07); neuropathy was 




In many developed countries, owing to adequate national 
registry systems, it has been possible to document the 
notable improvement achieved in recent years regarding 
the epidemiology, treatment, follow-up, and prevention 
of complications of T1DM. The EURODIAB study, which 
included most of the European countries and 30 million 
children, and the DIAMOND study, which included 84 million 
children from 112 centers in 57 countries, were initiated in 
the 1990s (12,13). Information about T1DM rapidly increased 
along with the data of these large, well-organized record 
systems. Developing a national registry system for T1DM, 
the incidence of which varies among races and countries, is 
of great importance for the prevention of microvascular and 
macrovascular complications (14). 
The present study aimed to provide a first step in the 
development of a national T1DM registry system by evaluating 
the records of 1 032 T1DM patients who were diagnosed in 
childhood and followed at 12 centers in Turkey. Epidemiologic 
data of the patients, as well as their state of metabolic control, 
presence of concomitant other autoimmune diseases and that 
of microvascular and acute complications were assessed.
It is known that the incidence of T1DM increases with 
age and peaks in puberty. In the present study, 27.1% of the 
patients were in the 0-4.99 year age group, 42.6% were in 
the 5-9.99 year age group, and 27.9% were in the 10-14.99 
year age group at the time of diagnosis. In the EURODIAB 
study, the distribution of patients among age groups at the 
time of diagnosis in 2005 was found as follows: 24% were in 
0-4 year age group, 35% were in 5-9 year age group, and 41% 
were in 10-14 year age group. In that particular study, these 
rates were estimated to be 29%, 37% and 34%, respectively, 
in 2020 (15). In the DIAMOND study group, the incidence 
increased with age. The pooled data of the DIAMOND study 
group demonstrated that those in the 5-9 year age group had 
a 1.62 times higher risk [95% confidence intervals (CI), 1.57-
1.66], and those in the 10-14 year age group had 1.94 times 
higher risk (95% CI, 1.89-1.98) than that of the 0-4 years olds 
(13). Similar to other studies showing no marked female 
dominance, the present study revealed a female-to-male 
ratio of 1.02 in frequency of autoimmune diseases, a finding 
which is on the contrary of female preponderance in other 
autoimmune diseases.  
In the present study, mean HbA1c level was found to be 
significantly higher in the pubertal group as compared to the 
prepubertal group. This might have resulted from increased 
insulin resistance and impaired compliance with treatment in 
puberty. Approximately 80% of the patients in the present 
study were on flexible insulin therapy and 6% were on 
CSII. The rate of patients with good metabolic control was 
higher in the group receiving CSII as compared to the group 
receiving flexible insulin therapy. Previous studies have also 
demonstrated that CSII therapy is much more successful 
than flexible insulin therapy in achieving metabolic control and 
in preventing complications (16,17).
It is known that the prevalence rates of autoimmune 
thyroid disease and GSE are higher in patients with T1DM 
compared to the healthy population (18). In a study conducted 
in Turkey on 38 patients with T1DM, the rates of autoimmune 
thyroid disease and GSE were reported to be 31.5% and 7.8%, 
respectively (19). In another study from Turkey, Karaguzel et 
al (20) reported the rate of thyroid autoantibody positivity to 
be 38.6% and the rate of antiendomysial antibody positivity 
to be 3.5%. In their study, Mantovani et al (21) identified 
autoimmune thyroid disease in 16.7% of 474 patients with 
T1DM. In a multicenter study conducted in Germany, Kaspers 
et al (22) screened approximately 20 000 T1DM patients and 
reported the celiac antibody positivity to be 6.7%. In the 
present study, we demonstrated that 12% of the patients had 
autoimmune thyroid disease and 4.3% had GSE.
The rate of severe hypoglycemia was 4.9% in the present 
study group, and no significant difference was determined 
among the groups with good, moderate and poor metabolic 
control in terms of the number of hypoglycemic attacks in the 
past year (p>0.05). However, the frequency of hypoglycemia 
reported in this study might not reflect the real value, since 
it was calculated based on the data recorded by the patients 
or their relatives. Blasetti et al (23) performed a longitudinal 
study on 195 children with T1DM and followed them for 7.5 
years. They reported that the rate of severe hypoglycemic 
attacks was 9.4% in one year and that hypoglycemic attacks 
were not associated with HbA1c levels, with daily insulin 
requirements, or with insulin regimens used. In a study 
performed by Rewers et al (24) on 1 243 T1DM patients 
aged 0 to 19 years, the frequency of severe hypoglycemia 
was reported to occur in 19% of the cases in the course of 
one year and was lower in females as compared to males. 
These authors showed that the frequency decreased with 
increasing age and increased with longer diabetes duration 
and with presence of concomitant psychiatric disease. They 
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Tab le 5. Mean numbers of severe hypoglycemia and ketoacidosis epi-
sodes according to glycemic control
Attacks within the past Group 1 Group 2 Group 3 p
year (number/patient/year)
Severe hypoglycemia 0.04±0.21 0.04±0.31 0.08±0.55 0.58*
Ketoacidosis 0 0.05±0.27 0.07±0.58 0.02**
*No significant difference among the groups.
**p=0.007 for Group 1 vs. Group 2; p=0.008 for Group 1 vs. Group 3; p=0.91 
for Group 2 vs. Group 3
Group 1: HbA1c level (<7.5%); Group 2: HbA1c level (7.5%-9.1%); Group 3: 
HbA1c level (≥9.0%) 
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also did not find an association between hypoglycemia 
and HbA1c level or insulin dose. In the present study, the 
rate of ketoacidosis, another acute complication of T1DM, 
was found to be 5.2% in the course of one year and was 
significantly lower in the group with good metabolic control 
as compared to the groups with moderate or poor metabolic 
control. Rewers et al (24) reported this rate to be 8% in a 
year in both genders, and found that the risk increased with 
age in girls, as well as with high HbA1c levels and need for 
high insulin doses, length of diabetes duration, presence of 
psychiatric disease, and absence of health insurance. In a 
multicenter study based on the data of approximately 29 000 
T1DM patients under the age of 20 years from Germany and 
Austria, total frequency of ketoacidosis was reported to be 
5.9%; 4.9% of the ketoacidosis patients had presented with 
one episode, and 1.0% of the patients had presented with 
recurrent episodes (25). While the frequency of ketoacidosis 
was not found to be associated with the type of treatment 
and diabetes duration in the above-mentioned study, the 
rate of diabetic ketoacidosis was reported to be significantly 
higher in females, in children with migration background, and 
in those in their early teenage years (25). 
T1DM is an important risk factor for dyslipidemia and 
cardiovascular diseases (5). In the present study, the 
prevalence of dyslipidemia was 17.5% and the majority 
(75.2%) of the cases with dyslipidemia were prepubertal. 
In their longitudinal study performed on 895 children and 
adolescents with T1DM, Marcovecchio et al (26) reported 
the rates of patients with high total cholesterol, high non-
HDL cholesterol, high triglyceride, and high LDL-cholesterol 
levels to be 18.6%, 25.9%, 20.1%, and 9.6%, respectively. 
They also reported that sustained lipid abnormalities were 
associated with age, duration, BMI, and HbA1c. In the present 
study as well, dyslipidemia was found to be significantly 
associated with older age and higher HbA1c levels; however, 
no difference was found between those with and without 
dyslipidemia in terms of diabetes duration.
The frequency of diabetic neuropathy was found to be 
2.7% in the present study. While neuropathy was associated 
with age and diabetes duration, no association was found 
with mean HbA1c level. In the 13th and 14th year of the 
Epidemiology of Diabetes Interventions and Complications 
(EDIC) study, the frequency of confirmed clinical neuropathy 
was reported to be 22% and 29% in the groups receiving 
intensive and conventional therapy, respectively (27). Lloyd 
et al (28) found the incidence of distal symmetric neuropathy 
to be 13% during a 4-year follow-up period. These studies 
demonstrated that neuropathy was associated with diabetes 
duration, age, and HbA1c level. The reason of lower neuropathy 
frequency in the present study might be the cross-sectional 
nature of the study and the young age of the patients. 
The frequency of retinopathy, another microvascular 
complication of diabetes, was 1.4% in the present study 
group. In the 10th year of the EDIC study, the frequency of 
proliferative retinopathy was found to be 6.1% and 19.6%, 
and the frequency of non-proliferative retinopathy was found 
to be 6.3% and 19.6% in the groups receiving intensive 
and conventional therapy, respectively (29). Hammes et al 
(30) reported the frequency of any type of retinopathy to be 
27.4% and the frequency of advanced retinopathy (severe 
non-proliferative or proliferative diabetic retinopathy) to be 
8%. They demonstrated that the development of retinopathy 
was correlated with diabetes duration, HbA1c level, and 
smoking, and that the risk was higher for the male gender. 
In the present study, development of retinopathy was found 
to be associated with longer diabetes duration and older age, 
while no association was identified between development of 
retinopathy and mean HbA1c level. Again, the lower rate of 
retinopathy found in the present study might be attributed to 
the design of the study as well as to the younger age of the 
patients. 
Persistent microalbuminuria was observed in 5.4% of the 
cases. Although the frequency of microalbuminuria was found 
to increase with age and was found to be more common 
in the pubertal cases, no association was present between 
microalbuminuria and mean HbA1c level. In their study on 27 805 
patients with T1DM, Raile et al (31) determined the frequencies 
of microalbuminuria, macroalbuminuria, and end-stage renal 
insufficiency to be 3.3%, 0.28%, and 0.73%, respectively. 
In that particular study, they estimated the frequency of 
microalbuminuria to be 25.4% and macroalbuminuria or end stage 
renal insufficiency to be 9.4% at the end of a 40-year follow-up. 
They reported that diabetes duration, high blood pressure, and 
high LDL-cholesterol level were risk factors for microalbuminuria.
In conclusion, our findings indicate that although the 
majority of the patients in the present study were using 
insulin analogues, poor glycemic control was common, and 
chronic complications were encountered. These findings also 
show that to be able to provide appropriate therapy and care 
service for all T1DM patients, each country needs to develop 
its own registry system and a health care system enabling the 
monitoring of these patients for many years.
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